Edwards receives fda approval for sapien 3 with alterra prestent for transcatheter pulmonic valve replacement

Irvine, calif., dec. 20, 2021 /prnewswire/ -- edwards lifesciences (nyse: ew) today announced it received approval from the u.s. food and drug administration (fda) for the use of the edwards sapien 3 transcatheter valve with the alterra adaptive prestent (sapien 3 with alterra) for patients with severe pulmonary regurgitation.
EW Ratings Summary
EW Quant Ranking